What's in Fundacion SEIMC-GESIDA's pipeline?

Fundacion SEIMC-GESIDA has 10 drugs in our index: 9 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Fundacion SEIMC-GESIDA's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, GlaxoSmithKline, ViiV Healthcare, Bristol-Myers Squibb, National Cancer Institute (NCI).

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/fundacion-seimc-gesida.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Fundacion SEIMC-GESIDA — Portfolio Competitive Intelligence Brief

Fundacion SEIMC-GESIDA pipeline: 9 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

9 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
ELV/COBI/FTC/TAF	ELV/COBI/FTC/TAF	marketed	Antiretroviral combination therapy (integrase inhibitor + NRTI + NtRTI + pharmacokinetic booster)	HIV integrase, HIV reverse transcriptase	Infectious Disease / Virology
DTG/3TC/ABC + ELV/COBI/FTC/TAF	DTG/3TC/ABC + ELV/COBI/FTC/TAF	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase	Infectious Disease / Virology
AZT+3TC+ABV (Trizivir)	AZT+3TC+ABV (Trizivir)	marketed	Nucleoside reverse transcriptase inhibitor (NRTI) combination	HIV reverse transcriptase	Infectious Disease / Virology
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4	Infectious Disease / Virology
HPV9v	HPV9v	marketed	Recombinant vaccine	Human papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52, 58	Oncology / Immunology / Infectious Disease
Ritonavir boosted Atazanavir + Lamivudine	Ritonavir boosted Atazanavir + Lamivudine	marketed	Antiretroviral combination (protease inhibitor + nucleoside reverse transcriptase inhibitor)	HIV protease; HIV reverse transcriptase	Infectious Disease / Virology
Ritonavir boosted Atazanavir + 2 NRTIs	Ritonavir boosted Atazanavir + 2 NRTIs	marketed	Protease inhibitor combination antiretroviral therapy	HIV protease, HIV reverse transcriptase	Infectious Disease
Dolutegravir/Lamivudine as a single pill	Dolutegravir/Lamivudine as a single pill	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase	Infectious Disease / Virology
Emtricitabine/tenofovir or abacavir/lamivudine	Emtricitabine/tenofovir or abacavir/lamivudine	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor (NRTI)	HIV reverse transcriptase	Infectious Disease / Virology

Therapeutic area mix

Infectious Disease / Virology · 7
Infectious Disease · 2
Oncology / Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
ViiV Healthcare · 2 shared drug classes
Bristol-Myers Squibb · 2 shared drug classes
National Cancer Institute (NCI) · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
AgeneBio · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fundacion SEIMC-GESIDA:

Cite this brief

Drug Landscape (2026). Fundacion SEIMC-GESIDA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fundacion-seimc-gesida. Accessed 2026-05-16.